Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US76029N1063
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00L8Z22R1
REPL
Replimune Group Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Replimune Group Inc
ISIN
US76029N1063
TICKER
REPL
MIC
XNAS
REUTERS
REPL.OQ
BLOOMBERG
REPL US
Wed, 05.08.2026       Replimune Group
US76029N1063

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVES...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Replimune Group
US76029N1063

Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Replimune Group
US76029N1063

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The i...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Replimune Group
US76029N1063

Instrument ID [10351] (7R8 - US76029N1063) suspended...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Replimune Group
US76029N1063

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Replimune Group
US76029N1063

Law Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REPLIMUNE GROUP INC. (REPL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENT...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Replimune Group
US76029N1063

The Law Offices of Frank R. Cruz announces an investigation of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON REPLIMUNE GROUP INC. (REPL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.06.2026       Replimune Group
US76029N1063

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.06.2026       Replimune Group
US76029N1063

FDA decision expected by August 2, 2026 FDA decision expected by August 2, 2026...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.05.2026       Replimune Group
US76029N1063

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 30.05.2026       Replimune Group
US76029N1063

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Replimune Group
US76029N1063

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path for...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Replimune Group
US76029N1063

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       Replimune Group
US76029N1063

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Replimune Group
US76029N1063

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Replimune Group
US76029N1063

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Replimune Group
US76029N1063

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics Licens...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Replimune Group
US76029N1063

Instrument ID [10351] (7R8 - US76029N1063) suspended...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Replimune Group
US76029N1063

April 10, 2026 Target Action Date for RP1 in Advanced Melanoma April 10, 2026 Target Action Date for RP1 in Advanced Melanoma...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       Replimune Group
US76029N1063

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 07.11.2025       Replimune Group
US76029N1063

Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 fa...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Replimune Group
US76029N1063

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Replimune Group
US76029N1063

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.10.2025       Replimune Group
US76029N1063

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the Euro...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. F...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclu...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encourage...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sat, 20.09.2025       Replimune Group
US76029N1063

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If yo...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sat, 20.09.2025       Replimune Group
US76029N1063

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 20, 2025 On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The la...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.09.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faru...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       Replimune Group
US76029N1063

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the company announced that it completed a Type A meeting with the F...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encourage...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       Replimune Group
US76029N1063

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete respons...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.09.2025       Replimune Group
US76029N1063

REPL Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Sept. 16, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The la...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encourage...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.09.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faru...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The la...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.09.2025       Replimune Group
US76029N1063

REPL Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Sept. 11, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encourage...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclu...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.09.2025       Replimune Group
US76029N1063

REPL Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.09.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink